Related Experiment Video
Updated: Aug 5, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Chronic pentamidine aerosol prophylaxis does not induce QT prolongation
C Thalhammer1, J R Bogner, G Lohmöller
1Medizinische Poliklinik, Universität München.
The Clinical Investigator
|April 1, 1993
Summary
Pentamidine aerosol prophylaxis, used for Pneumocystis pneumonia prevention in HIV patients, does not cause QT prolongation or long-QT syndrome, unlike intravenous pentamidine. This study found no cardiac risks associated with inhaled pentamidine use.
Area of Science:
- Pharmacology
- Cardiology
- Infectious Disease
Background:
- Intravenous pentamidine is associated with QT prolongation and Torsade de pointes tachycardias.
- Pentamidine aerosol prophylaxis is a common preventative treatment for Pneumocystis pneumonia in HIV-infected individuals.
Purpose of the Study:
- To investigate whether pentamidine aerosol prophylaxis induces QT prolongation.
- To assess the risk of long-QT syndrome associated with inhaled pentamidine.
Main Methods:
- A cross-sectional study compared QT intervals corrected for heart rate (QTc) in HIV patients on pentamidine aerosol prophylaxis, HIV patients without pentamidine, and non-HIV controls.
- A longitudinal study assessed QTc in HIV patients before and during long-term pentamidine aerosol prophylaxis.
- QTc measurements were performed blindly for treatment status.
Main Results:
- No significant difference in QTc was observed between patients receiving pentamidine aerosol prophylaxis, HIV-negative controls, and HIV-positive controls not on pentamidine.
- Long-term pentamidine aerosol prophylaxis did not alter QTc intervals in HIV-infected patients.
- The study found no evidence of QT prolongation or increased risk of long-QT syndrome with inhaled pentamidine.
Conclusions:
- Pentamidine aerosol prophylaxis does not induce QT prolongation.
- Unlike intravenous administration, inhaled pentamidine is not associated with an increased risk of long-QT syndrome.
- This finding supports the cardiac safety of pentamidine aerosol prophylaxis in HIV management.
More Related Videos
Related Concept Videos
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.